Editorial Expression of Concern: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Cory M Johannessen^{1

2

3}, Laura A Johnson^{1

2

4}, Federica Piccioni¹, Aisha Townes¹, Dennie T Frederick⁵, Melanie K Donahue¹, Rajiv Narayan¹, Keith T Flaherty⁵, Jennifer A Wargo⁵, David E Root¹, Levi A Garraway^{6

7

8}

Affiliations

¹ The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
³ Harvard Medical School, Boston, Massachusetts, USA.
⁴ Graduate Program in Cell and Molecular Physiology, Sackler School of Graduate Biomedical Sciences, School of Medicine, Tufts University, Boston, Massachusetts, USA.
⁵ Department of Surgical Oncology, Medical Oncology and Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Levi_Garraway@dfci.harvard.edu.
⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Levi_Garraway@dfci.harvard.edu.
⁸ Harvard Medical School, Boston, Massachusetts, USA. Levi_Garraway@dfci.harvard.edu.

Cory M Johannessen et al. Nature. 2025 May.

. 2025 May;641(8062):E7.

doi: 10.1038/s41586-025-09027-6.

¹ The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
³ Harvard Medical School, Boston, Massachusetts, USA.
⁴ Graduate Program in Cell and Molecular Physiology, Sackler School of Graduate Biomedical Sciences, School of Medicine, Tufts University, Boston, Massachusetts, USA.
⁵ Department of Surgical Oncology, Medical Oncology and Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Levi_Garraway@dfci.harvard.edu.
⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Levi_Garraway@dfci.harvard.edu.
⁸ Harvard Medical School, Boston, Massachusetts, USA. Levi_Garraway@dfci.harvard.edu.

No abstract available

Expression of concern for

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. Johannessen CM, et al. Nature. 2013 Dec 5;504(7478):138-42. doi: 10.1038/nature12688. Epub 2013 Nov 3. Nature. 2013. PMID: 24185007 Free PMC article.